

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 June 2023 (29.06.2023)



(10) International Publication Number
WO 2023/122656 A1

(51) International Patent Classification:

C12N 15/113 (2010.01) A61P 13/12 (2006.01)
A61K 31/7088 (2006.01)

(21) International Application Number:

PCT/US2022/082128

(22) International Filing Date:

21 December 2022 (21.12.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/292,581 22 December 2021 (22.12.2021) US
63/340,254 10 May 2022 (10.05.2022) US

(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(72) Inventors: **HAAS, Mary E.**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **LOTTA, Luca Andrea**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **BARAS, Aris**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **FERREIRA, Manuel Allen Revez**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **DEVALARA-**

JA-NARASHIMHA, Kishor; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **MORTON, Lori**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **SUN, Luanluan**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(74) Agent: **LEGAARD, Paul K.** et al.; Armstrong Teasdale LLP, 7700 Forsyth Boulevard, Suite 1800, St. Louis, Missouri 63105 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,

(54) Title: TREATMENT OF KIDNEY DISEASES WITH ANGIOPOIETIN LIKE 3 (ANGPTL3) INHIBITORS

(57) Abstract: The present disclosure provides methods of treating a subject having a kidney disease or at risk of developing a kidney disease by administering an Angiotensin Like 3 (ANGPTL3) inhibitor, and methods of identifying subjects having an increased risk of developing a kidney disease.




Figure 1

WO 2023/122656 A1

[Continued on next page]

TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*